01 / GLP-1 visualizer
Tirzepatide Weight Loss VisualizerTirzepatide Weight Loss Visualizer: Preview Your Transformation
Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, is producing some of the most impressive weight loss results in medical history—with users losing 20-25% of their body weight on average. This dual GLP-1/GIP receptor agonist surpasses semaglutide-based medications in effectiveness, but the aggressive appetite suppression means many users struggle to maintain adequate nutrition and muscle mass. Our AI visualizer shows you both potential outcomes: rapid transformation with facial volume loss versus a healthy, sustainable approach that preserves your appearance while still achieving dramatic results.
See "The Risk"
What rapid weight loss looks like: gaunt cheeks, hollow temples, aged appearance.
See "The Glow"
What healthy transformation looks like: defined jawline, volume retention, radiant appearance.
- 100% Private & Secure
- Photorealistic AI
- Instant Results

Before

Rapid Loss

Healthy Glow
02 / Try it
Try it on your own photo.
Upload one photo, pick a goal, and see a realistic preview in about 30 seconds.
A clear, front-facing photo works best
Your original photo is never saved on our servers or used to train AI. It’s sent securely to our AI image provider to create your image, then discarded.
Free to preview · pay only to unlock the full-resolution image.
03 / Three stages
Three Stages. Your Choice.
The same weight loss can look completely different depending on how you lose it. See all three stages of your transformation journey.
01 · AI exampleBefore
Your starting point before any weight loss
02 · AI exampleRapid Loss - "The Risk"
Rapid weight loss without proper nutrition - gaunt, hollow appearance
03 · AI exampleHealthy Glow - "The Goal"
Slower-loss example: muscle retained, fuller face
04 / Background
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that represents a significant advancement over semaglutide medications. By activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, it provides superior appetite suppression and metabolic effects. Available as Mounjaro (for type 2 diabetes) and Zepbound (for weight management), tirzepatide consistently produces 20-25% body weight reduction in clinical trials—but this aggressive weight loss makes strategic nutrition and training absolutely essential.
Why This Matters
Tirzepatide represents the cutting edge of weight loss medication—dual GIP/GLP-1 activation produces results that exceed even Wegovy. Clinical trials show 20-25% body weight reduction, which for a 200-pound person means 40-50 pounds lost. This is extraordinary...and extraordinarily risky if not managed properly. The dual receptor mechanism suppresses appetite more aggressively than any medication before it. Users frequently report struggling to eat enough—period. Getting adequate protein becomes a daily challenge. In SURMOUNT studies, participants losing weight on tirzepatide without resistance training lost significant lean mass along with fat. This lean mass depletion shows most dramatically in the face, where there's minimal muscle to begin with. Our visualizer shows you the spectrum: what 20-25% body weight loss looks like when it's all fat and muscle loss (gaunt, aged) versus when it's primarily fat loss with muscle preservation (defined, vibrant). The medication is the same. The weight loss is the same. The facial outcome is completely different based on your nutrition and training approach.
05 / How it works
How It Works
Three simple steps to see your transformation paths
- 01
Upload Your Photo
Use any clear photo of yourself. Full body works best, but face photos work too. The AI analyzes your facial structure and fat distribution.
- 02
Select Your Transformation Path
Choose "Tirzepatide Transformation (Both Paths)" to see side-by-side comparisons of rapid loss versus healthy transformation. The AI generates both versions.
- 03
Compare & Plan Your Approach
See both versions side-by-side. Use them to inform your nutrition strategy, training plan, and weight loss pacing decisions. Knowledge is power.
06 / GLP-1 tools
Looking for other GLP-1 visualizers?
Explore our full suite of weight loss medication visualizers
Ozempic Face Visualizer
See both transformation paths before you start
Ozempic Before & After Simulator
See realistic Ozempic transformation results
Wegovy Transformation Visualizer
Preview your Wegovy weight loss journey
Mounjaro Body Visualizer
Visualize Mounjaro transformation results
Semaglutide Face Visualizer
See semaglutide facial transformation effects
Zepbound Weight Loss Visualizer
See Zepbound transformation results
07 / Questions
Frequently Asked Questions
- Q.01
How much weight loss should I expect with tirzepatide?
Clinical trials show average weight loss of 20-25% of body weight over 72 weeks, which is significantly more than semaglutide medications (15-20%). For a 200 lb person, that's 40-50 lbs of weight loss. Our visualizer helps you see what this transformation looks like when done correctly versus when done too rapidly without muscle preservation.
- Q.02
Is tirzepatide more likely to cause facial volume loss than Ozempic?
The greater total weight loss with tirzepatide means there's more opportunity for facial changes if not managed properly. However, the facial volume loss isn't caused by the medication itself—it's caused by rapid weight loss without muscle preservation. Whether you're on tirzepatide, semaglutide, or any weight loss approach, the key is gradual loss with high protein and strength training.
- Q.03
Can I switch between different transformation goals in the visualizer?
The visualizer shows two distinct paths: "Rapid Loss" (what happens with aggressive deficits and no muscle preservation) and "Healthy Glow" (gradual loss with proper nutrition and training). This helps you understand the impact of your approach, not just the medication. Same drug, same weight loss, dramatically different appearance—it's all about HOW you lose the weight.